AbbVie reported the company’s fourth-quarter 2021 and full-year financial results on Feb. 2, with worldwide net reviews up 7.4% to $14.89 billion for the quarter. Total revenues for 2021 were $56 billion. The company’s anchor product remains Humira, which will begin to lose exclusivity in 2023.
The U.S. Food and Drug Administration approved the first treatment that addresses IL-13 cytokine in adults diagnosed with moderate to severe atopic dermatitis.
Four months after forging a collaboration to develop an experimental atopic dermatitis treatment, Amgen and Japan’s Kyowa Kirin are beginning to see the fruits of that deal with positive Phase II data for AMG 451/KHK4083, a potential first-in-class anti-OX40 monoclonal antibody.
Pfizer Inc.’s experimental drug to treat patients with moderate-to-severe atopic dermatitis met the main goals of improving symptoms in adult patients compared to a rival treatment from Regeneron Pharmaceutical Inc.
During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.
Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.
Pfizer received positive top-line results from the Phase III JADE REGIMEN study, examining the investigational oral once-daily Janus kinase 1 (JAK1) inhibitor abrocitinib for the treatment of severe atopic dermatitis.
AbbVie’s Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in a second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
A look at the U.S. Food and Drug Administration’s drug approval review calendar.
Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.